Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesDividends payablesLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Oramed Pharmaceuticals (ORMP) Assets (2016 - 2026)

Oramed Pharmaceuticals filings provide 15 years of Assets readings, the most recent being $230.9 million for Q4 2025.

  • Quarterly Assets rose 48.68% to $230.9 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $230.9 million through Dec 2025, up 48.68% year-over-year, with the annual reading at $230.9 million for FY2025, 48.68% up from the prior year.
  • Assets hit $230.9 million in Q4 2025 for Oramed Pharmaceuticals, up from $220.5 million in the prior quarter.
  • Across five years, Assets topped out at $230.9 million in Q3 2023 and bottomed at $61.7 million in Q1 2021.
  • Average Assets over 5 years is $167.5 million, with a median of $163.4 million recorded in 2022.
  • The largest annual shift saw Assets surged 345.31% in 2021 before it fell 29.6% in 2024.
  • Oramed Pharmaceuticals' Assets stood at $182.4 million in 2021, then fell by 11.4% to $161.6 million in 2022, then skyrocketed by 36.44% to $220.6 million in 2023, then decreased by 29.6% to $155.3 million in 2024, then skyrocketed by 48.68% to $230.9 million in 2025.
  • Per Business Quant, the three most recent readings for ORMP's Assets are $230.9 million (Q4 2025), $220.5 million (Q3 2025), and $161.7 million (Q2 2025).